Our research projects

Helping children in sub-Saharan Africa with endemic Burkitt Lymphoma get diagnosed earlier.

Testing nanoparticles as a way of getting drugs where they are needed for acute myeloid leukaemia.

Creating antibodies in the lab to treat diffuse midline gliomas and testing their effectiveness.

Looking at molecular makeup and MRIs to characterise infant ependymoma.

Stopping protein activity to stop anaplastic large cell lymphomas from growing.

Developing more effective treatments for patients who have a low chance of survival, while reducing treatment and side effects for other patients.

Our proposal will deliver novel, less toxic targeted therapies with the potential to advance current treatment regimens for B-ALL. This will improve current outcomes, reduce side-effects in B-ALL patients and ultimately lead to a better quality of life for patients and their families.

Glo-BNHL trial is an international trial that will recruit children across the globe with relapse BNHL and assign them to the trial to receive a novel therapy. We are requesting funds to conduct biological studies alongside the trial to improve our understanding of this cancer.

Ewing sarcoma is the second most common bone tumour in young people. The primary goal of this project is to fast-track a targeted drug combination for evaluation in clinical trials, with the aim of improving outcomes and minimising treatment associated morbidities for Ewing sarcoma patients.